GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nexalin Technology Inc (NAS:NXL) » Definitions » Altman Z2-Score

Nexalin Technology (Nexalin Technology) Altman Z2-Score : -91.88 (As of May. 29, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Nexalin Technology Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

Nexalin Technology has a Altman Z2-Score of -91.88, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Nexalin Technology's Altman Z2-Score or its related term are showing as below:

NXL' s Altman Z2-Score Range Over the Past 10 Years
Min: -484.72   Med: -59.97   Max: -20.85
Current: -91.88

During the past 4 years, Nexalin Technology's highest Altman Z2-Score was -20.85. The lowest was -484.72. And the median was -59.97.


Nexalin Technology Altman Z2-Score Historical Data

The historical data trend for Nexalin Technology's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexalin Technology Altman Z2-Score Chart

Nexalin Technology Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Altman Z2-Score
- -373.83 -25.48 -64.32

Nexalin Technology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.16 -41.17 -55.61 -64.32 -91.88

Competitive Comparison of Nexalin Technology's Altman Z2-Score

For the Medical Devices subindustry, Nexalin Technology's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nexalin Technology's Altman Z2-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nexalin Technology's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Nexalin Technology's Altman Z2-Score falls into.



Nexalin Technology Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Nexalin Technology's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.7255+3.26*-27.5508+6.72*-1.7329+1.05*4.5897
=-91.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2024:
Total Assets was $2.83 Mil.
Total Current Assets was $2.56 Mil.
Total Current Liabilities was $0.51 Mil.
Retained Earnings was $-78.08 Mil.
Pre-Tax Income was -1.041 + -0.781 + -2.297 + -0.822 = $-4.94 Mil.
Interest Expense was 0 + -0.019 + -0.005 + -0.006 = $-0.03 Mil.
Total Liabilities was $0.51 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(2.563 - 0.507)/2.834
=0.7255

X2=Retained Earnings/Total Assets
=-78.079/2.834
=-27.5508

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-4.941 - -0.03)/2.834
=-1.7329

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(2.327 - 0)/0.507
=4.5897

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Nexalin Technology has a Altman Z2-Score of -91.88 indicating it is in Distress Zones.


Nexalin Technology  (NAS:NXL) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Nexalin Technology Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Nexalin Technology's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Nexalin Technology (Nexalin Technology) Business Description

Traded in Other Exchanges
N/A
Address
1776 Yorktown, Suite 550, Houston, TX, USA, 77056
Nexalin Technology Inc design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy.
Executives
Marilyn Elson 10 percent owner, officer: Ms. Elson serves as CFO 32 CAMLET COURT, ROSELAND NJ 07068
Rick Morad director 6331 CHAGRIN RIVER ROAD, BENTLEYVILLE OH 44022
Mark White director, officer: President/CEO 1776 YORKTOWN STREET, SUITE 550, HOUSTON TX 77056
David Owens director, officer: Chief Medical Officer 4545 HARRIS TRAIL NW, ATLANTA GA 30327
Alan Kazden director 3435 CONSUELO DRIVE, CALABASAS CA 91302
Leonard Osser other: Spouse
Ben Hu director 7021 EDGERTON ROAD, NORTH ROYALTON OH 44133

Nexalin Technology (Nexalin Technology) Headlines

From GuruFocus

Nexalin Technology Provides 2022 Year-End Business Update

By sperokesalga sperokesalga 03-27-2023

Nexalin Technology CEO Provides Letter to Shareholders

By Stock market mentor Stock market mentor 01-05-2023